

Market Announcement

24 July 2026

Radiopharm Theranostics Limited (ASX: RAD) – Suspension from Quotation

The securities of Radiopharm Theranostics Limited ('RAD') will be suspended from quotation immediately under Listing Rule 17.2 at the request of RAD, pending the release of an announcement by RAD.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in RAD's request for voluntary suspension; or
- the release of the announcement to the market.

RAD's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Compliance

24 July 2026

Yulia Gurdina
Principal Adviser, Listings Compliance
ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

Via email

Dear Yulia

Radiopharm Theranostics Limited (ASX: RAD)

Request for Voluntary Suspension

Further to the trading halt requested and granted on Wednesday, 22 July 2026, and in accordance with ASX Listing Rule 17.2, Radiopharm Theranostics Limited (ASX: RAD) (the **Company**) requests voluntary suspension of its securities effective immediately pending an announcement by the Company in relation to a material capital raising, which the Company anticipates will be made prior to commencement of trading on Monday, 27 July 2026.

Reporting of the proposed capital raising has been delayed to enable the finalisation of international investor subscription and settlement documentation.

The Company is not aware of any reason why its securities should not be suspended or of any other information necessary to inform the market about the suspension.

Please contact me if you require any further information.

Yours sincerely,

Amritha Sushil
Joint Company Secretary